Evidence map›Paper›PMID 15466379›Full record

ArticleThe American journal of pathology2004

Clinicobiological, immunophenotypic, and molecular characteristics of monoclonal CD56-/+dim chronic natural killer cell large granular lymphocytosis.

Margarida Lima, Julia Almeida, Andrés García Montero, Maria dos Anjos Teixeira, Maria Luís Queirós, Ana Helena Santos, Ana Balanzategui, Alexandra Estevinho, Maria del Cármen Algueró, Paloma Barcena and 8 more

Open access · bronzeAbstract read
In one paragraph

Article in The American journal of pathology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 64 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Large granular lymphocytic leukemia: a brief review.American journal of blood research · 2022
    Review
  6. High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  7. Review
  8. Article
  9. βInternational journal of medical sciences · 2017
    Article
  10. Article
  11. T-cell/Natural killer-cell neoplasms presenting as leukemia- Case series from single tertiary care center.International journal of hematology-oncology and stem cell research · 2016
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Chronic natural killer lymphoproliferative disorders: characteristics of an international cohort of 70 patients.Annals of oncology : official journal of the European Society for Medical Oncology · 2014
    Article
  17. Natural killer cells in human autoimmune disorders.Arthritis research & therapy · 2013
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 2 countries.

Margarida LimaServiço de Hematologia, Unidade de Citometria, Hospital Geral de Santo António, Rua D Manuel II, s/n, 4099-001 Porto, Portugal. mmc.lima@clix.pt.
Julia Almeida
Andrés García Montero
Maria dos Anjos Teixeira
Maria Luís Queirós
Ana Helena Santos
Ana Balanzategui
Alexandra Estevinho
Maria del Cármen Algueró
Paloma Barcena
Sónia Fonseca
Maria Luís Amorim
José Manuel Cabeda
Luciana Pinho
Marcos Gonzalez
Jesus San Miguel
Benvindo Justiça
Alberto Orfão
Hospital de Santo António · PTCentro de Investigación del Cáncer · ESComplejo Hospitalario de Salamanca · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Indolent natural killer (NK) cell lymphoproliferative disorders include a heterogeneous group of patients in whom persistent expansions of mature, typically CD56(+), NK cells in the absence of any clonal marker are present in the peripheral blood. In the present study we report on the clinical, hematological, immunophenotypic, serological, and molecular features of a series of 26 patients with chronic large granular NK cell lymphocytosis, whose NK cells were either CD56(-) or expressed very low levels of CD56 (CD56(-/+dim) NK cells), in the context of an aberrant activation-related mature phenotype and proved to be monoclonal using the human androgen receptor gene polymerase chain reaction-based assay. As normal CD56(+) NK cells, CD56(-/+dim) NK cells were granzyme B(+), CD3(-), TCRalphabeta/gammadelta(-), CD5(-), CD28(-), CD11a(+bright), CD45RA(+bright), CD122(+), and CD25(-) and they showed variable and heterogeneous expression of both CD8 and CD57. Nevertheless, they displayed several unusual immunophenotypic features. Accordingly, besides being CD56(-/+dim), they were CD11b(-/+dim) (heterogeneous), CD7(-/+dim) (heterogeneous), CD2(+) (homogeneous), CD11c(+bright) (homogeneous), and CD38(-/+dim) (heterogeneous). Moreover, CD56(-/+dim) NK cells heterogeneously expressed HLA-DR. In that concerning the expression of killer receptors, CD56(-/+dim) NK cells showed bright and homogeneous CD94 expression, and dim and heterogeneous reactivity for CD161, whereas CD158a and NKB1 expression was variable. From the functional point of view, CD56(-/+dim) showed a typical Th1 pattern of cytokine production (interferon-gamma(+), tumor necrosis factor-alpha(+)). From the clinical point of view, these patients usually had an indolent clinical course, progression into a massive lymphocytosis with lung infiltration leading to death being observed in only one case. Despite this, they frequently had associated cytopenias as well as neoplastic diseases and/or viral infections. In summary, we describe a unique and homogeneous group of monoclonal chronic large granular NK cell lymphocytosis with an aberrant activation-related CD56(-/+dim)/CD11b(-/+dim) phenotype and an indolent clinical course, whose main clinical features are related to concomitant diseases.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorBlotting, SouthernCD56 AntigenChronic DiseaseCytokinesFemaleFlow CytometryGene Rearrangement, T-LymphocyteHematologic DiseasesHumansImmunophenotypingKiller Cells, NaturalLymphocytosisBiomarkers, TumorCD56 AntigenCytokines

Identifiers

PMID15466379
PMCPMC1618630
OpenAlexW2169377554

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.